Amneal Pharmaceuticals
NEWS
Two weeks after announcing concerns about high-levels of carcinogens in popular diabetes drugs, the U.S. Food and Drug Administration announced the first voluntary recalls of this class of drugs manufactured by five companies.
The companies are facing questions in a criminal probe regarding their marketing distribution practices related to the sale of opioids.
BioSpace scanned the WARN (Worker Adjustment and Retraining Notification) notices across the country and compiled a small list of recent layoffs across the industry.
The drug is approved for use for management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, adjunctive therapy for partial-onset seizures in patients 17 years of age and older, fibromyalgia, and neuropathic pain associated with spinal cord injury.
More than 600 employees will lose their jobs as the companies reshape their corporate strategies.
Amneal did not specify any layoffs as part of the cut, but did note that employees affected by the decision will be provided comprehensive transition plan.
Pharma, biotech and life science companies strengthen leadership teams, with news from Vertex, Arvinas, Provention, Enterome, and more.
The U.S. Food and Drug Administration (FDA) approved Bridgewater, NJ-based Amneal Pharmaceuticals’ generic version of Novartis’ Exelon Patch (Rivastigmine Transdermal System) for dementia related to Alzheimer’s and Parkinson’s diseases.
Nirmal Mulye, chief executive officer of Missouri-based Nostrum Laboratories, is looking to take over Martin Shkreli’s mantle of being the poster-boy for drastic drug price increases.
JOBS
IN THE PRESS